enfuvirtide

It is important to use enfuvirtide regularly to get the most benefit.

Each vial of enfuvirtide is for a single use only.

There may be other drugs that can interact with enfuvirtide.

Carefully follow all instructions about giving yourself an enfuvirtide injection.

Stop using enfuvirtide and call your doctor at once if you have any of these serious side effects:

You may need a dose adjustment or special tests to safely use enfuvirtide.

Maraviroc and enfuvirtide are the two currently available agents in this class.

Trimeris began development on enfuvirtide in 1996 and initially designated it T-20.

Do not use enfuvirtide in larger amounts, or use it for longer than recommended by your doctor.

Do not draw your enfuvirtide dose into a syringe until you are ready to give yourself an injection.

Store unmixed enfuvirtide powder at room temperature away from moisture and heat.

Your pharmacist can provide more information about enfuvirtide.

You should not breast-feed while you are using enfuvirtide.

By virtue of its peptide nature, enfuvirtide is marketed in injectable form.

Do not use enfuvirtide as your only HIV medication.

Symptoms of an enfuvirtide overdose are unknown.

Fusion inhibitor drugs such as enfuvirtide block the fusion process by binding to gp41.

Fusion and entry inhibitors, such as enfuvirtide and maraviroc.

Before using enfuvirtide, tell your doctor if you are using a blood thinner such as warfarin (Coumadin).

You may not be able to use enfuvirtide, or you may need dosage adjustments or special tests during treatment.

Enfuvirtide originated at Duke University, where researchers formed a pharmaceutical company known as Trimeris.

The lyophilised enfuvirtide powder must be reconstituted by the patient and administered twice daily by subcutaneous injection.

Enfuvirtide Common side effects of enfuvirtide include skin itchiness, swelling, and pain at the site of the injection.